Hunter syndrome drug safety tracked in extended trial
NCT ID NCT06031259
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is a follow-up for people with Hunter syndrome and cognitive problems who already took part in earlier studies. It aims to check the long-term safety of the drug idursulfase-IT given with Elaprase. About 6 children and adults will continue their same treatment to monitor for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTER SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Femme Mere Enfant
Bron, Auvergne-Rhône-Alpes, 02 69229, France
-
Hospital for Sick Children
Toronto, Ontario, M5G1X8, Canada
-
M.A.G.I.C. Clinic
Calgary, Alberta, T2E 7Z4, Canada
-
University of British Columbia
Vancouver, British Columbia, V6T1Z3, Canada